Publications by authors named "Naoual El Jonhy"
Objective: To compare the effectiveness and safety of Celsior® crystalloid solution to St Thomas® solution as cardioplegia in pediatric arterial switch surgery.
Methods: A retrospective study was conducted on 180 patients who underwent arterial switch operation (ASO) between 2005 and 2019. The patients were divided into two groups: the St Thomas group receiving St Thomas solution and the Celsior® group receiving Celsior® solution.
Article Synopsis
- The COVERT-MI trial tested high-dose colchicine in patients with acute STEMI and found no reduction in infarct size, while the colchicine group showed an increase in left ventricular thrombus compared to placebo.
- A one-year follow-up revealed no significant differences in major adverse cardiovascular events (MACEs) between the colchicine and placebo groups, with 39.6% of participants experiencing MACEs overall.
- Despite no excess adverse events linked to colchicine, there was a trend toward fewer heart failure events and no notable differences in quality of life scores between the two groups after one year.
Article Synopsis
- This study investigated if colchicine, an anti-inflammatory medication, could reduce heart damage and remodeling after a ST-segment-elevation myocardial infarction (a type of heart attack) by comparing it to a placebo in a double-blind trial.
- The trial included 192 patients, with no significant differences in heart damage or remodeling observed between the colchicine and placebo groups at both 5 days and 3 months post-treatment.
- However, patients taking colchicine experienced higher rates of gastrointestinal side effects compared to those on the placebo, suggesting a potential drawback of the treatment.
Article Synopsis
- Inflammatory processes significantly worsen myocardial damage during ischemia-reperfusion injury in STEMI, leading to serious complications like heart failure and poor recovery.
- Colchicine, known for its strong anti-inflammatory effects, has shown a promising 50% reduction in infarct size in a phase II trial, compared to placebo, for acute STEMI patients undergoing primary percutaneous coronary intervention (PPCI).
- The ongoing COVERT-MI trial aims to confirm these findings by comparing a short course of colchicine treatment to placebo in STEMI patients, measuring infarct size and other cardiac health indicators over 5 days.